XSPRAY — Xspray Pharma publ AB Share News
0.000.00%
Last trade - 00:00- SEK631.98m
- SEK659.11m
Brief: Xspray Pharma Q2 Loss Before Tax Widens To SEK 17.0 Mln
Brief: Xspray Pharma Q1 Pre-Tax Loss Widens To SEK 13.9 Million
Brief: Xspray Pharma AB (Publ) - Q4 Earnings Before Tax Amounted Sek -14,972 Thousand
Brief: Nomination Committee Proposes Anders Ekblom As New Chairman Of The Board In Xspray Pharma
Brief: Xspray Pharma Announces Results From Additional Bioequivalence Study
Brief: XSpray Pharma Reports Positive Results From A Study With Dasatinib During Omeprazole Treatment
Brief: Xspray Pharma To Await Result Of Two Ongoing Clinical Studies Before Submitting Its ANDA Application
Brief: Xspray Pharma Q3 Pretax Loss Widens To SEK 11.6 Million
Brief: XSpray Pharma AEO Bookrunner Says Offering Size Up To C. 1.9M Shares
Brief: XSpray: Positive Preliminary Results From HyNap-Dasa Study
Brief: XSpray Pharma Chairman Not To Stand For Re-Election
Brief: XSpray Announces Positive Stability Data On HyNap-Dasa Tablets
Brief: Xspray Pharma Says First Study With HyNap-Dasa Does Not Fulfil Requirements
Brief: Xspray Pharma Approved For Listing On Nasdaq Stockholm
Brief: Xspray Receives Notification Of Manufacturing Approval And Provides Update On Clinical Studies
Brief: Xspray Pharma Q4 Loss Before Tax Widens To SEK 18.7 Mln
Brief: XSpray Pharma Gets Three New Patents In The U.S. For HyNap-Dasa
Brief: XSpray Pharma Gets Three New Patents In US
Brief: XSpray Pharma Gets New U.S. Patent For HyNap-Dasa